Vaccines
An Introduction to Vaccines
Vaccines have substantially reduced morbidity and mortality from infectious diseases in the
developed world. Many vaccines, including those for measles and some influenza vaccines,
use live attenuated viruses. The COVID-19 pandemic has led to unprecedented rates of
vaccine development, raising hopes that other vaccines might be made on a comparable
timescale in the future. In particular, it has established the clinical utility of mRNA vaccines,
which have demonstrated high potency, capacity for rapid development and potential for
low-cost manufacture and safe administration. In addition, other approaches, including
nucleic acid-based vaccines, recombinant DNA platforms, virus-like particle (VLP) based
vaccines, non-replicating viral vectors, recombinant nanoparticles and peptide vaccines in
active clinical development.
Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
